305 related articles for article (PubMed ID: 30741690)
1. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
3. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
4. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
[TBL] [Abstract][Full Text] [Related]
5. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
6. Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
Yoo HS; Lee EC; Chung SJ; Ye BS; Sohn YH; Seong JK; Lee PH
Sci Rep; 2022 Jul; 12(1):12631. PubMed ID: 35879381
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
8. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
Lago-Rodriguez A; Ponzo V; Jenkinson N; Benitez-Rivero S; Del-Olmo MF; Hu M; Koch G; Cheeran B
Exp Brain Res; 2016 Dec; 234(12):3659-3667. PubMed ID: 27566172
[TBL] [Abstract][Full Text] [Related]
10. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
Hong JY; Sunwoo MK; Yoon JH; Kang SY; Sohn YH; Lee PH; Kim SH
PLoS One; 2020; 15(8):e0237472. PubMed ID: 32817705
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
Yoo HS; Chung SJ; Lee YH; Lee HS; Ye BS; Sohn YH; Lee PH
Neurology; 2019 Mar; 92(13):e1468-e1478. PubMed ID: 30796137
[TBL] [Abstract][Full Text] [Related]
13. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
14. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
Yoo HS; Choi YH; Chung SJ; Lee YH; Ye BS; Sohn YH; Lee JM; Lee PH
Ann Clin Transl Neurol; 2019 Nov; 6(11):2251-2260. PubMed ID: 31643140
[TBL] [Abstract][Full Text] [Related]
16. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Foltynie T; Cheeran B; Williams-Gray CH; Edwards MJ; Schneider SA; Weinberger D; Rothwell JC; Barker RA; Bhatia KP
J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):141-4. PubMed ID: 18977816
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Dias CMV; Leal DAB; Brys I
Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
[No Abstract] [Full Text] [Related]
18. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Suh DC; Pahwa R; Mallya U
J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
[TBL] [Abstract][Full Text] [Related]
19. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
Jourdain VA; Tang CC; Holtbernd F; Dresel C; Choi YY; Ma Y; Dhawan V; Eidelberg D
JCI Insight; 2016 Sep; 1(15):e86615. PubMed ID: 27699242
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of striatal Ca
Caulfield ME; Vander Werp MJ; Stancati JA; Collier TJ; Sortwell CE; Sandoval IM; Manfredsson FP; Steece-Collier K
Neurobiol Dis; 2023 Jun; 181():106111. PubMed ID: 37001610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
